Sutcliffe JS, Nakao M, Christian S, et al. (1995). "Deletions of a differentially methylated CpG island at the SNRPN gene define a putative imprinting control region". Nat. Genet. 8 (1): 52–8. doi:10.1038/ng0994-52. PMID7987392.
Schulze A, Hansen C, Skakkebaek NE, et al. (1996). "Exclusion of SNRPN as a major determinant of Prader-Willi syndrome by a translocation breakpoint". Nat. Genet. 12 (4): 452–4. doi:10.1038/ng0496-452. PMID8630505.
Wirth J, Back E, Hüttenhofer A, et al. (2001). "A translocation breakpoint cluster disrupts the newly defined 3' end of the SNURF-SNRPN transcription unit on chromosome 15". Hum. Mol. Genet. 10 (3): 201–10. doi:10.1093/hmg/10.3.201. PMID11159938.
Dorsam RT, Tuluc M, Kunapuli SP (2005). "Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets". J. Thromb. Haemost. 2 (5): 804–12. doi:10.1111/j.1538-7836.2004.00692.x. PMID15099288.
Nakayama T, Hirano K, Hirano M, et al. (2004). "Inactivation of protease-activated receptor-1 by proteolytic removal of the ligand region in vascular endothelial cells". Biochem. Pharmacol. 68 (1): 23–32. doi:10.1016/j.bcp.2004.03.005. PMID15183114.
Shi X, Gangadharan B, Brass LF, et al. (2005). "Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis". Mol. Cancer Res. 2 (7): 395–402. PMID15280447.
Heider I, Schulze B, Oswald E, et al. (2005). "PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism". Oncol. Res. 14 (10): 475–82. PMID15559761.
Tantivejkul K, Loberg RD, Mawocha SC, et al. (2005). "PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism". J. Cell. Biochem. 96 (3): 641–52. doi:10.1002/jcb.20533. PMID16052512.